Preventive Pharmacologic Therapy for Kidney Stone Disease
Wilson Sui,Kevin Shee,Marshall Stoller
DOI: https://doi.org/10.1001/jamanetworkopen.2024.28927
2024-08-24
JAMA Network Open
Abstract:Urolithiasis is a disease of morbidity, rarely resulting in mortality, with increasing prevalence and high recurrence rates. 1 Considerable time and energy have been spent on identifying and implementing strategies to prevent subsequent kidney stone episodes. As most kidney stones are calcium based, thiazide diuretics have traditionally been used to decrease urinary calcium levels and thereby reduce recurrence rates. 2 Although a recent high-profile study, the Hydrochlorothiazide for Kidney Stone Recurrence Prevention [NOSTONE] trial, appears to argue against the use of diuretics given their negative findings, subanalyses from their own study suggest that higher doses of thiazides were associated with decreased kidney stone recurrence and more pronounced decreases in urinary calcium. 3 In their study, Hsi and colleagues 4 used a unique dataset built from linking patients between Litholink and Medicare. They found that higher thiazide dosages were associated with more pronounced reductions in urinary calcium levels and that the increased reduction in urinary calcium levels was associated with decreased kidney stone recurrence rates. The main findings of their study suggest that clinicians need to first identify patients with hypercalciuria and then aggressively treat them with thiazide diuretics to yield the most benefit in reducing kidney stone recurrence. The study by Hsi and colleagues 4 implies that patients should be aggressively screened for hypercalciuria and other urinary analyte abnormalities associated with kidney stone recurrence through tools such as the 24-hour urine test to identify those who may benefit the most from preventive pharmacologic intervention. The 24-hour urine test is cumbersome for patients to perform, and many clinicians have difficulties with interpretation due to the frequent presence of more than 1 abnormality, complex interactions between abnormalities, and borderline values. Frustratingly, patients who form kidney stones can have normal 24-hour urine collection results and those who do not form kidney stones can have abnormal 24-hour urine collection results. It is not surprising then that only 7% of patients at high risk undergo the 24-hour urine test 5 and that, among those with an initial abnormality, only 16% receive repeat testing within 6 months. 6 Dichotomizing patients into simply high and low risk of kidney stone formation may not be sensitive enough to stratify their risk of kidney stone recurrence. Finding more efficient methods to risk stratify patients for testing or iterating new testing modalities may thus be critical. Although urine calcium levels were measured, hypercalciuria was not an inclusion criteria in many of the randomized clinical trials evaluating thiazide diuretics, including NOSTONE. 2 ,3 However, thiazides demonstrated a protective effect in most of these trials, arguing for the utility of empiric therapy. These trials, however, are heterogeneous in terms of outcomes and adjunctive dietary management; therefore, the purported benefits of empiric therapy may be overstated. Among individuals who formed kidney stones in 3 prospective cohorts of health care professionals, the rates of hypercalciuria were 45% to 54%. 7 In comparison, 63% of participants in the NOSTONE trial had hypercalciuria, which may in part explain the contradictory findings. Directed preventive pharmacologic therapy may result in the most efficient reduction in recurrence of kidney stones, especially if higher dosages of medications are used. However, most clinicians likely prefer to start at low dosages and then titrate the dosage based on adverse effects and efficacy. In kidney stone disease, efficacy is ultimately defined by kidney stone events, which are often not a practical end point to use in practice, as symptomatic events are often separated by years or decades. Silent events, typically defined by radiographic changes, are also suboptimal as an end point because they require close, consistent monitoring with frequent radiation exposure that may have significant interobserver variability depending on the modality used. To titrate to the appropriate dosages suggested by Hsi and colleagues, 4 performing subsequent 24-hour urine testing for all patients to decide when to adjust dosing may be critical to success in modifying the disease course of recurrent nephrolithiasis. Published: August 22, 2024. doi:10.1001/jamanetworkopen.2024.28927 Open Access: This is an open access article distributed under the terms of the CC-BY License. © 2024 Sui W et al. JAMA Network Open . Corresponding Author: Kevin Shee, MD, PhD, Department of Urology, University of California, San Francisco, 400 Parnassus Ave, A610, San Francisco, CA 94143 (Kevin.Shee@ucsf.edu). Conflic -Abstract Truncated-
medicine, general & internal